Back to top
more

Arvinas (ARVN)

(Delayed Data from NSDQ)

$27.14 USD

27.14
840,209

-0.61 (-2.20%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $27.18 +0.04 (0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Arvinas (ARVN) Up on Promising Interim Data on Cancer Candidates

by Zacks Equity Research

Arvinas (ARVN) announces promising interim data on its two clinical stage pipeline candidates, ARV-471 and ARV-110, for treating breast cancer and prostate cancer, respectively.

New Strong Sell Stocks for November 16th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -12.07% and 0.40%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Arvinas, Inc. (ARVN) Q2 Earnings Expected to Decline

by Zacks Equity Research

Arvinas, Inc. (ARVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arvinas, Inc. (ARVN) Upgraded to Buy: Here's Why

by Zacks Equity Research

Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

How Arvinas (ARVN) Stock Stands Out in a Strong Industry

by Zacks Equity Research

Arvinas (ARVN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Arvinas, Inc. (ARVN) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Arvinas, Inc. (ARVN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of 5.08% and 20.46%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Is Arvinas (ARVN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (ARVN) Outperforming Other Medical Stocks This Year?

Why You Shouldn't Bet Against Arvinas (ARVN) Stock

by Zacks Equity Research

Arvinas (ARVN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Arvinas, Inc. (ARVN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -5.66% and 2.69%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

What's in the Offing for Emerson (EMR) in Q1 Earnings?

by Zacks Equity Research

Emerson's (EMR) fiscal Q1 earnings are likely to have gained from steady demand in process and hybrid end markets. Weak global discrete manufacturing market might have been a concern.

Will Arvinas Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Arvinas.

Arvinas, Inc. (ARVN) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

Arvinas, Inc. (ARVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Will Arvinas Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Arvinas.